Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 8;10(3):405.
doi: 10.3390/vaccines10030405.

Nasal Nanovaccines for SARS-CoV-2 to Address COVID-19

Jialu Huang  1 , Yubo Ding  2 , Jingwei Yao  2 , Minghui Zhang  1 , Yu Zhang  1 , Zhuoyi Xie  1 , Jianhong Zuo  1   2   3
Affiliations
Review

Nasal Nanovaccines for SARS-CoV-2 to Address COVID-19

Jialu Huang et al. Vaccines (Basel). .

Abstract

COVID-19 is still prevalent around the globe. Although some SARS-CoV-2 vaccines have been distributed to the population, the shortcomings of vaccines and the continuous emergence of SARS-CoV-2 mutant virus strains are a cause for concern. Thus, it is vital to continue to improve vaccines and vaccine delivery methods. One option is nasal vaccination, which is more convenient than injections and does not require a syringe. Additionally, stronger mucosal immunity is produced under nasal vaccination. The easy accessibility of the intranasal route is more advantageous than injection in the context of the COVID-19 pandemic. Nanoparticles have been proven to be suitable delivery vehicles and adjuvants, and different NPs have different advantages. The shortcomings of the SARS-CoV-2 vaccine may be compensated by selecting or modifying different nanoparticles. It travels along the digestive tract to the intestine, where it is presented by GALT, tissue-resident immune cells, and gastrointestinal lymph nodes. Nasal nanovaccines are easy to use, safe, multifunctional, and can be distributed quickly, demonstrating strong prospects as a vaccination method for SARS-CoV-2, SARS-CoV-2 variants, or SARS-CoV-n.

Keywords: COVID-19; nanovaccine; nasal vaccination.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Figure 1
Figure 1
Different routes of vaccination produce different types of immunity at different sites. Oral vaccines along the digestive tract to the GALT, which produce mucosal and systemic immunity. Aerosol vaccines reach BALT by inhalation into the bronchi, which produce mucosal and systemic immunity. Nasal vaccines produce mucosal and systemic immunity at NALT.
Figure 2
Figure 2
Functional NPs in SARS-CoV-2 vaccines mainly include promoting cell uptake of antigens, protecting antigens, and fully mimicking pathogens. Part of the structure of SARS-CoV-2 was selected to be wrapped in a nanocapsule, or superfluous structures removed from SARS-CoV-2 were replaced with NPs.
Figure 3
Figure 3
(1) Dendritic cells (DC) pass through mucosal epithelial cells to capture NPs in the mucosal layer. (2) NPs can also passively permeate through epithelial junctions to access the underlying DC. (3) A pocket enriched in APC (macrophages-Mφ, DC, and lymphocytes T) created by the M cells, which perform the sampling of the luminal antigens so that the immune cells contact the NP/antigen. (4) NPs can also enter cells through endocytosis and deliver the antigens to cells.
See this image and copyright information in PMC

References

    1. WHO Coronavirus (COVID-19) Dashboard. [(accessed on 26 November 2021)]. Available online: https://covid19.who.int/
    1. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. doi: 10.1038/s41422-020-0282-0. - DOI - PMC - PubMed
    1. Wilt T.J., Kaka A.S., MacDonald R., Greer N., Obley A., Duan-Porter W. Remdesivir for Adults With COVID-19: A Living Systematic Review for American College of Physicians Practice Points. Ann. Intern. Med. 2021;174:209–220. doi: 10.7326/M20-5752. - DOI - PMC - PubMed
    1. Lamb Y.N. Remdesivir: First Approval. Drugs. 2020;80:1355–1363. doi: 10.1007/s40265-020-01378-w. - DOI - PMC - PubMed
    1. Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C., Hohmann E., Chu H.Y., Luetkemeyer A., Kline S., et al. Remdesivir for the Treatment of COVID-19—Final Report. N. Engl. J. Med. 2020;383:1813–1826. doi: 10.1056/NEJMoa2007764. - DOI - PMC - PubMed

LinkOut - more resources